TheraRadar
← Back
Data updated: Jul 17, 2026

HALOZYME THERAP

Biotech
MetabolicOncologyDermatology Execution: Good

HALOZYME THERAP is a biotechnology company focused on Metabolic, Oncology, Dermatology.

2005
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics

HALOZYME THERAP at a Glance

  • Fast trial execution (12 months median completion)

HALOZYME THERAP's Key Drugs

HALOZYME THERAP's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

HALOZYME THERAP's Recent FDA Approvals

New NDA/BLA approvals for HALOZYME THERAP over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

HALOZYME THERAP's Therapeutic Areas

HALOZYME THERAP's approved drugs and pipeline span 4 therapeutic areas, led by Metabolic and Oncology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 47%
0 drugs Phase 2: 5 Phase 1: 5
Oncology 41%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 7
Dermatology 6%
0 drugs Phase 2: 1
Gastroenterology 6%
0 drugs Phase 1: 2

HALOZYME THERAP's Top Competitors

HALOZYME THERAP's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Eli Lilly, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Gastroenterology, Metabolic
Eli Lilly big-pharma
Metabolic, Oncology, Dermatology
Takeda big-pharma
Metabolic, Gastroenterology, Oncology
KING PHARMS LLC big-pharma
Dermatology, Oncology, Metabolic
Pfizer big-pharma
Oncology, Dermatology

HALOZYME THERAP Pipeline Snapshot

HALOZYME THERAP has 22 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 7 Phase 2 and 14 Phase 1.

1
Phase 3
7
Phase 2
14
Phase 1

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q1 2028
—
Hypogonadism, Male
Estimated · fresh NCT06689085

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Metabolic pipeline focus
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/2 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges